New horizons in bladder cancer research
Joost L. Boormans(Erasmus MC), Bernd J. Schmitz‐Dräger, Ellen C. Zwarthoff(Erasmus MC), Peter C. Black(University of British Columbia), Stephen B. Williams(Cedars-Sinai Medical Center), Roland Seiler(University of British Columbia), Roman Nawroth(TUM Klinikum), Peter J. Goebell(Friedrich-Alexander-Universität Erlangen-Nürnberg), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center)
Cited by 10
Related Papers
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo.
|Proceedings of the National Academy of Sciences|1989|493
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
|Nature Communications|2021|381